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INTRODUCTION
Mundy et al. first reported evidence showing that statins
may have anabolic effects on bone, in which statins stimu-
lated significant new bone formation in rodents (1). Statins
act on the mevalonate pathway in osteoblasts and enhance
the expression of the bone morphogenic protein-2 (BMP-2),
which is an important growth factor for osteoblast differen-
tiation. It is believed that BMP-2 upregulation mediates the
bone forming effect of statins. Additionally, statins act on the
same pathway upstream of the bisphosphonates in osteoclasts
via the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, leading to decreased protein preny-
lation, which is essential for a normal osteoclast function (2).
As a result of these reports, many clinical investigations
have reexamined the datasets from observational and cohort
trials to assess the effect of statins on the bone metabolism
and fracture risk. Some studies have reported beneficial effects
(3-6), whereas others have not (7-9). In a randomized con-
trolled trial, simvastatin had no significant effect on bone
mineral density and bone turnover in postmenopausal osteo-
penic women (10).
In rodents, orally administered statins have been shown to
increase the bone volume in some (1, 11), but not all studies
(12). Skoglund et al. recently reported that statins enhance
the net bone formation and improve the healing of fractures
in mice (13). In addition, in vitro studies have shown that
statins enhance the osteoblastic synthesis of BMP-2 and pro-
mote osteoblastic differentiation in a mouse osteoblastic cell
line (14), in a human osteosarcoma cell line (15) and in murine
embryonic stem cells (16).
Many of the studies investigating the effects of statins on
osteoblasts were performed either on an animal cell line, or
another immortalized cell line and studies that examine the
influence of statin on the proliferation of bone cells are scarce.
In the present study, we investigated whether simvastatin, a
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The Effect of Simvastatin on the Proliferation and Differentiation of
Human Bone Marrow Stromal Cells 
Statins have been postulated to affect the bone metabolism. Recent experimental
and epidemiologic studies have suggested that statins may also have bone protec-
tive effects. This study assessed the effects of simvastatin on the proliferation and
differentiation of human bone marrow stromal cells (BMSCs) in an ex vivo culture.
The bone marrow was obtained from healthy donors. Mononuclear cells were iso-
lated and cultured to osteoblastic lineage. In the primary culture, 10
-6 M simvastatin
diminished the mean size of the colony forming units-fibroblastic (CFU-Fs) and en-
hanced matrix calcification. At near confluence, the cells were sub-cultured. There-
after, the alkaline phosphatase (ALP) activities of each group were measured by
the time course of the secondary culture. Simvastatin increased the ALP activity in
a dose dependent manner, and this stimulatory effect was more evident during the
early period of culture. A 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bro-
mide (MTT) assay was performed during the secondary culture in order to estimate
the effect of simvastatin on the proliferation of human BMSCs. When compared to
the control group, simvastatin significantly decreased the proliferation of cells of each
culture well. 10
-6 M of simvastatin also significantly enhanced the osteocalcin mRNA
expression level. This study shows that simvastatin has a stimulatory effect on bone
formation through osteoblastic differentiation, and has an inhibitory effect on the
proliferative potential of human BMSCs 
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HMG-CoA reductase inhibitor, regulates the proliferation
and differentiation of osteoblasts using primary human bone
marrow stromal cells.
MATERIALS AND METHODS
Culture of human bone marrow stromal cells
Bone marrow was harvested from the iliac crest of healthy
donors. They were donors of bone marrow transplant, and
informed consent was obtained from all donors. The mononu-
clear cells were separated using Ficoll-Hypaque (1.077 g/mL,
Sigma-Aldrich Co, St. Louis, MO, U.S.A.) and cultured as
described (17). In brief, they were seeded in culture flasks
including  -MEM (Sigma) at a density of 4×105 cells/mL,
and incubated at 37℃ in a humidified atmosphere contain-
ing 95% air and 5% CO2. Collagen was not pre-treated in
culture flasks. The medium was composed of 20% heat inac-
tivated fetal calf serum (FCS) (Life Technologies, NY, U.S.A.),
100 unit/mL penicillin-streptomycin (Life Technologies),
and 10-8 M vitamin-K (Sigma). On the next day, 10 mM  -
glycerophosphate (Sigma) and 50  g/mL ascorbic acid were
added without changing the media. Subsequently, the cul-
ture flasks were left alone without disturbing them so as to
promote cell attachment for 4 to 5 days. After the attachment
period, the culture medium was replaced with fresh  -minimum
essential medium (MEM) including 20% heat inactivated FCS,
100 unit/mL penicillin-streptomycin, 10-8 M vitamin-K, 10
mM -glycerophosphate and 50  g/mL ascorbic acid. The
media was supplemented with simvastatin (dissolved in 75%
ethanol, kindly provided by Merk, NJ, U.S.A.) at a concentra-
tion of 10-8 M and 10-6 M. The cells were then fed at 2-day
intervals thereafter. For the subculture, the mononuclear cells
were cultured without simvastatin to near-confluence. The
cells were then sub-cultured after 0.25% trypsin/1 mM EDTA
(Life Technologies) digestion and seeded in 6 well culture
plates at a density of 5×104 cells/mL. In the secondary culture,
the cells were maintained in  -MEM including 10% heat inac-
tivated FCS and treated with either the vehicle or 10-8 or 10-6
M simvastatin for the indicated time period.
Staining and determination of colony number and size
Crystal violet staining was performed after 15 days of the
primary culture. The cell layers were rinsed with phosphate
buffered saline, and stained with 0.5% crystal violet for 5 min
at room temperature. The number of colony-forming fibrob-
lastic units (CFU-Fs) was counted in duplicate by both the
naked eye and by using inverted optical microscopy (Olym-
pus BH2; Olympus Denmark, Albertslund, Denmark). A
single observer who blinded the conditions used in the study
counted all the colonies. The CFU-Fs that were 1 mm in dia-
meter or larger were counted. The colony size was determined
by image analysis of the plate using Sigma Scan pro 4.0 for
Windows (SPSS, Inc., Chicago, IL, U.S.A.).
Matrix calcification-calcium determination
After 17 days of the primary culture, the cells were washed
thoroughly with PBS and incubated overnight at room tem-
perature in 500  L of 0.1 N HCl to dissolve the calcium min-
eral from the calcified matrix. The supernatants were collect-
ed and the calcium level was determined using the o-cresolph-
thalein complexone method (Sigma kit, Procedure #587,
Sigma). The cells were again washed with PBS and the pro-
tein was dissolved in 1 mL of 0.1 N NaOH/0.1% sodium
dodecyl sulfate overnight at room temperature. The protein
content was determined by the bicinchoninic acid (Sigma)
method (18), which was used to normalize the calcium data.
Alkaline phosphatase activity
The alkaline phosphatase (ALP) activities were measured at
3-day intervals for 12 days in the secondary culture period.
The HBMS cells in 6-well plates were washed three times
with phosphate buffered saline. The cell layers were lysed with
0.1% Triton X-100 at 1 mL per well. 1 M Tris-HCl 500  L,
5 mM MgCl2 100  L and 5 mM p-nitrophenyl phosphate
(Sigma) 100  L were added to the 300  L lysate. The sam-
ples were incubated for 30 min at 37℃. The absorbance was
read immediately after incubation at a wavelength of 410 nm
using a plate reader (19). Bovine serum albumin was used as
a standard for measuring the protein concentration using the
bicinchoninic acid method. The enzyme activities are expressed
as U/mg protein.
MTT assay 
The 5-diphenyltetrazolium bromide (MTT, thiazoyl blue,
Sigma) assay was used to measure the cellular growth and
survival (20). The total cell number in each well was esti-
mated from the results of MTT assay. The cells were seeded
in 6 well plates and treated in the same manner as with the
alkaline phosphatase activity assay. The MTT assay was per-
formed at 5-day intervals for 15 days in the secondary cul-
ture period. The MTT was diluted to a final concentration
of 0.5 mg/mL in the culture media. The cells were incubat-
ed for 2 hr, and the media was carefully removed. The for-
mazan crystals were dissolved in acidified isopropanol (40
mM HCl in isopropanol) and the absorbance was determined
at a wavelength of 590 nm.
Reverse trascriptase-polymerase chain reaction (RT-PCR)
The cells were seeded in 6 well culture plates at a density of
1×105 cells per well and grown for 12 days. After 2 days of
simvastatin treatment, the RNA was extracted using TRIzol
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(Life Technologies) and isolated according to the manufacture’s
protocol. A RNA pellet was dissolved in diethylpyrocarbonate
treated (DEPC) H2O, quantified by its absorbance at a wave-
length of 260 nm, and stored at -70℃. cDNA was synthesized
from 1  g of the total RNA. The RNA was mixed with a
random primer, and incubated for 10 min at 65℃. The 10×RT
buffer, MgCl2 (5 mM), dNTP (1.0 mM of each dATP, dGTP,
dCTP, and dTTP), RNase inhibitor (50 U), and AMV-reverse
transcriptase (20 U, Roche Molecular Biochenicals, India-
nopolis, IN, U.S.A.) were then added, and the reaction was
incubated for at least 4 hr at 42℃. The PCR reactions were
performed in duplicate. The cDNA (1  L) was amplified in a
20 L  reactionmixture containing the 10×PCR buffer, MgCl2
(1.5 mM), dNTPs (0.2 mM of each dATP, dGTP, dCTP and
dTTP), primers (0.5 mM for each sense and antisense primer),
and Taq DNA polymerase (0.025 U/mL, Roche). The sense
and antisense primers, 5′ -CGGAGTCAACGGATTTGGTC-
GTAT-3′ , 5′ -AGCCTTCTCCATGGTGGTGAAGAC-3′ ;
5′ -CCTGAAAGCCGATGTGGTC-3′ , 5′ -CTCACA CTCC-
TCGCCCTAT-3′(Bioneer, Daejeon, Korea), respectively, were
used for the amplification of the glyceraldehyde-3-phosphate
dehydrogenase (GADH, Bioneer) and osteocalcin. The PCR
products were separated in a 3% agarose gel and visualized by
ethidium bromide staining. The band intensities were quan-
titated using Gel Doc 1000
� and the Molecular Analyst Soft-
ware Version 1.4.1 (Bio-Rad, U.S.A.). Each cycle consisted of
96℃45 sec, 62℃45 sec, 72℃2 min, for various cycle num-
bers depending on the gene abundance, terminating in 72℃
for 5 min. For semi-quantitative PCR, the linear range of am-
plification was first established and the PCR cycles were chosen
to be within that range. The expression of osteocalcin was com-
pared to GAPDH, which served as the normalizing control.
Statistics 
The values are expressed as a mean±SEM. Statistical analy-
sis was performed using the Wilcoxon signed rank test. A p
value <0.05 was considered significant.
RESULTS
Effects of simvastatin on CFU-Fs formation 
The mean number of CFU-Fs obtained in the control group
and the 10-8 M simvastatin group was 77±21 and 73±20,
respectively. There was a trend for the mean number of CFU-
Fs to increase after 10-6 M treatment (94±21), but this was
not statistically significant (Fig. 1, 2A). 
The CFU-F sizes were examined to determine if simvas-
tatin influences the proliferative potential of the bone mar-
row stromal cells. 10-6 M simvastatin significantly decreased
the mean CFU-F size compared to the control (11.6±2.8
mm2, 22.9±5.0 mm2, p<0.05), (Fig. 1, 2B).
Effect of simvastatin on matrix calcification 
During the primary culture, the addition of simvastatin
stimulated matrix calcification, a late marker of osteoblastic
maturation. In the presence of 10-6 M simvastatin, matrix
calcification was increased by 1.6±0.15 fold, compared to
the control cultures (p<0.05), (Fig. 3). 
Alkaline phosphatase activity 
The alkaline phosphatase activity reached a maximum value
on day 3 of the secondary culture. Simvastatin increased the
alkaline phosphatase activity in a dose dependent manner,
and the increase in the activity was significant at a statin con-
centration of 10-6 M at 3 (p<0.01) and 6 days (p<0.05) in the
culture compared to the control cultures. The stimulating
effect of simvastatin was not showed during the late period
Fig. 1. CFU-F production from human bone marrow cells of the same donor. 4×10
6 nucleated cells, which were derived from the iliac crest,
were plated in 10-cm Petri dishes in  -MEM with 20% FCS heat-inactivated, 10 mM  -glycerophosphate and 50  g/mL ascorbic acid, and
grown for 15 days in the absence (A) or presence of 10
-8 M (B) and 10
-6 M (C) simvastatin. Simvastatin was added after the attachment
period (4 to 5 days). The colonies were fixed and stained with crystal violet.
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of the secondary cultures (Fig. 4).
MTT assay 
During the secondary culture, the number of cells progres-
sively increased, and the addition of simvastatin decreased
cell proliferation in a dose dependent manner. At 5, 10, and
15 days of culture, 10-6 M simvastatin consistently decreased
the number of cells compared to the control (p<0.01) and at
10 and 15 days of culture, 10-8 M simvastatin also decreased
the number of cells compared to the control (p<0.01), (Fig. 5).
Osteocalcin mRNA expression 
The presence of 10-6 M simvastatin for 48 hr enhanced the
osteocalcin mRNA expression level approximately 1.5 fold
compared to that in the unstimulated condition (p<0.05).
This effect was not evident after treatment with 10-8 M sim-
vastatin (Fig. 6).
DISCUSSION
This study showed that simvastatin, a HMG-CoA reductase
inhibitor, promoted osteoblastic differentiation in the human
BMSCs. Simvastatin stimulated the ALP activity, which is
an early osteoblastic differentiation marker, and enhanced
the expression of osteocalcin, which is a late osteoblastic dif-
ferentiation marker. Simvastatin also promoted the mineral-
ization of the matrix by the osteoblasts. These results are con-
Fig. 3. Effect of simvastatin on matrix calcification. 8×10
5 nucleated
cells were plated in 6 well plates in  -MEM with 20% FCS heat-inac-
tivated, 10 mM  -glycerophosphate, and 50  g/mL ascorbic acid.
After the attachment period, the stromal cells were treated with sim-
vastatin. The calcium content of the matrix was determined as des-
cribed in the text and normalized to the protein content. The normal-
ized value obtained from the cells incubated under the control con-
ditions was set at 100%, corresponding to 3.26±0.31 g  calcium/
g protein. The results are presented as a mean±SEM, n=11, each
performed in duplicate. *statistically different from control cultures,
p<0.05.
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Fig. 4. Effect of simvastatin on the ALP activity in the secondary cul-
ture of human marrow stromal cells. After confluence, 1×10
5 stromal
cells per well were subcultured in  -MEM with 20% FCS heat-inacti-
vated, 10 mM  -glycerophosphate, 50  g/mL ascorbic acid in 6 well
plates. The cells were treated with either the vehicle or 10
-8 or 10
-6 M
simvastatin for the indicated time period. The ALP activity was mea-
sured as described in the text and normalized to the protein content.
The results are shown as a mean±SEM. n=14, each performed in
duplicate. *statistically different from control cultures, p<0.05. 
� , p<0.01.
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Fig. 2. Effect of simvastatin on the number (A) and the size (B) of CFU-Fs. The bone marrow was aspirated from the iliac crest of 9 young donors.
Mononuclear cells were seeded in 10-cm dishes. Simvastatin was added at the appropriate concentrations after the attachment period. After
15 days, the cultures were fixed, stained, and the number and size of the CFU-Fs were determined. The results are shown as a mean±SEM.
*statistically different from control cultures, p<0.05.
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sistent with previous observations showing that the statins
enhanced osteogenesis in MC3T3-E1 cells (a clonal pre-osteo-
blastic cell line derived from mouse calvaria) (14) and murine
embryonic stem cells (16). Ohnaka et al. reported the stim-
ulatory effect of statin on the osteocalcin mRNA expression
level in primary culture of human osteoblasts prepared from
femur bone fragments (21). All these results and our findings
are in good agreement with the concept that statin may dif-
ferentiate the osteoblasts. This beneficial influence of simvas-
tatin on the bone metabolism might allow the statins to be-
come an effective anabolic agent for treating osteoporosis.
Simvastatin was chosen from various HMG-CoA reductase
inhibitors because different statins have been reported to have
a varying effect on the bone, with the lovastatin and pravas-
tatin exhibiting the least effect, and statins such as simvas-
tatin, atrovastatin, and cerivastatin exert greater effects (22).
In previous experiments investigating the effects of simvas-
tatin on osteoblastic differentiation in MC3T3-E1 cells, sig-
nificant effects were observed at a concentration of 10-7 M
and 10-8 M simvastatin (14). However, our results showed
that the stimulatory effects were evident only at 10-6 M sim-
vastatin. It is believed that this discrepancy results from the
different culture system and target cells. Human pharmacoki-
netic studies showed that maximum serum concentration of
simvastatin was 1.4×10-8 M when 40 mg of simvastatin was
administered (23).
Osteoblasts originate from osteoprogenitor cells in the bone
marrow stroma termed BMSCs or mesenchymal stem cells
(24). During the in vitro culture, the BMSCs formed distinct
colonies of cells with a fibroblast morphology, colony-form-
ing units-fibroblastic (CFU-Fs) (25). It has been shown that
treatment with a number of bone anabolic agents is followed
by an increase in the number of CFU-Fs in ex vivo cultures
(26, 27). In our experiments, the number of CFU-Fs tends
to increase after simvastatin treatment, and simvastatin also
actively stimulates the osteoblastic differentiation of colonies,
as shown by the matrix calcification assay. Therefore, it is
likely that statins may stimulate the mobilization of osteo-
progenitor cells in the bone marrow, and their presence will
also enhance the differentiation of osteoprogenitor cells.
Treatment with BMP-2 increases the ALP activity and
osteocalcin production in human BMSCs (28), and stimulates
the ALP activity and collagen synthesis in primary cultures
of fetal calvarial osteoblasts (29). It is generally agreed that
the bone forming effects of the statins are associated with an
increased BMP-2 expression level (1). Our results are same
as those observed for BMP-2. Although, we did not examine
the changes in BMP-2 expression during the simvastatin treat-
ment, it is plausible that BMP-2 exerts its main role also in
the osteogenesis of the simvastatin stimulated human BMSCs.
This study also examined whether or not simvastatin affect-
ed the proliferation of BMSC in both the primary and sec-
ondary cultures. During the primary culture, the addition
of 10-6 M simvastatin led to a significant decrease in the colony
size, which is a marker of the proliferative potential. In the
secondary culture, simvastatin significantly decreased the cell
number compared to the untreated cells, which was consis-
tent throughout the culture period. This is not due to the
cytotoxicity of the dissolving vehicle because equal amounts
of ethanol were used in each treatment group and control.
Interestingly, these effects are similar to those observed with
Fig. 5. Effect of simvastatin on cell number in the secondary culture
of human marrow stromal cells. The cells were cultured as described
in Fig. 4 and treated with the vehicle or either doses (10
-8 or 10
-6 M) of
simvastatin for the indicated time period. The MTT assay was done
as described in the text. The results are presented as a mean±SEM,
n=22, each performed in duplicate. 
� statistically different from control
cultures, p<0.01.
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Fig. 6. Effect of simvastatin on osteocalcin gene expression as deter-
mined by RT-PCR. The cells were seeded in 6 well culture plates at
a density of 1×10
5 cells per well and grown for 12 days. The cells
were then treated for 2 days with the vehicle control or either doses
(10
-8 or 10
-6 M) of simvastatin. 1  g of the total RNA from each culture
was reverse transcribed and subjected to PCR for osteocalcin anal-
ysis. GAPDH mRNA expression was also examined by RT PCR as
an internal reference. Representative PCR band (A) and mean data
(B) of 22 experiments. The results are presented as a mean±SEM,
*statistically different from control cultures, p<0.05.Effect of Simvastatin on Human BMSCs  443
BMP-2. Treatment with rhBMP-2 reduced human BMSC
growth by 40%, as shown by the DNA content after 2-3
weeks of culture, compared to the untreated cells (30).
To the best of the authors’ knowledge, there is no report
on the effects of statins on cell growth and proliferation. The
implications of these findings are as yet uncertain. Several
mechanisms have been suggested to be involved in a bone
formation defect: a deficit in the bone marrow stromal cell
populations, a decrease in the osteoblastic growth and/or func-
tion and a lower proliferation rate of the osteoblast precursors
(31). It is difficult to weigh the effects of the proliferation
and differentiation on new bone formation; in our opinion,
either factors are important. Although the statins have ben-
eficial effects on the differentiation process, if the effects on
cell growth and proliferation are considerable, the net effects
would be less. The parathyroid hormone, a representative
anabolic agent, actually stimulates the proliferation as well
as the differentiation of osteoprogenitor cells (32, 33). Besides,
the insulin-like growth factor-I (IGF-I), which is another well-
known anabolic agent, has been shown to promote osteoblast
differentiation and osteoblast proliferation (34, 35). In fact,
many studies that examined the effects of statins on the frac-
ture incidence, the bone mineral density, and the biochemi-
cal makers of the bone turnover have been published, but
the results have been mixed (3-10, 36-42). Additional ran-
domized, prospective, trials with the use of the appropriate
statins, doses, and routes would solve these debates. In addi-
tion, it is suggested that the inhibitory effects of the statins
on bone cell proliferation should be considered before inter-
preting these results.
In conclusion, this study found that the HMG-CoA reduc-
tase inhibitor, simvastatin, is able to increase the alkaline
phosphatase activity, the osteocalcin expression level, and
the deposition of minerals in human BMSCs. These results
suggest that simvastatin has anabolic effects on the bone by
promoting osteoblastic differentiation. However, the inhibitory
function of the simvastatin on bone cell proliferation also
demonstrated that it might interfere with new bone forma-
tion. In the process of osteogenesis in vivo, it is difficult to
predict whether decreased proliferation or enhanced differ-
entiation would contribute more in the presence of statins,
and future studies will be needed to address this issue.
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